A snapshot of the Covid-19 pandemic among pregnant women in France.
Adult
Betacoronavirus
COVID-19
Coronavirus Infections
/ epidemiology
Extracorporeal Membrane Oxygenation
Female
France
/ epidemiology
Humans
Maternal Age
Noninvasive Ventilation
Outcome Assessment, Health Care
Oxygen
/ therapeutic use
Pandemics
Pneumonia, Viral
/ epidemiology
Pregnancy
Pregnancy Complications, Infectious
/ epidemiology
SARS-CoV-2
Severity of Illness Index
COVID 19
Lockdown
Respiratory complications
Risk factors
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
29
05
2020
accepted:
31
05
2020
pubmed:
9
6
2020
medline:
4
9
2020
entrez:
8
6
2020
Statut:
ppublish
Résumé
To describe the course over time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in French women from the beginning of the pandemic until mid-April, the risk profile of women with respiratory complications, and short-term pregnancy outcomes. We collected a case series of pregnant women with COVID-19 in a research network of 33 French maternity units between March 1 and April 14, 2020. All cases of SARS-CoV-2 infection confirmed by a positive result on real-time reverse transcriptase polymerase chain reaction tests of a nasal sample and/or diagnosed by a computed tomography chest scan were included and analyzed. The primary outcome measures were COVID-19 requiring oxygen (oxygen therapy or noninvasive ventilation) and critical COVID-19 (requiring invasive mechanical ventilation or extracorporeal membrane oxygenation, ECMO). Demographic data, baseline comorbidities, and pregnancy outcomes were also collected. Active cases of COVID-19 increased exponentially during March 1-31, 2020; the numbers fell during April 1-14, after lockdown was imposed on March 17. The shape of the curve of active critical COVID-19 mirrored that of all active cases. By April 14, among the 617 pregnant women with COVID-19, 93 women (15.1 %; 95 %CI 12.3-18.1) had required oxygen therapy and 35 others (5.7 %; 95 %CI 4.0-7.8) had had a critical form of COVID-19. The severity of the disease was associated with age older than 35 years and obesity, as well as preexisting diabetes, previous preeclampsia, and gestational hypertension or preeclampsia. One woman with critical COVID-19 died (0.2 %; 95 %CI 0-0.9). Among the women who gave birth, rates of preterm birth in women with non-severe, oxygen-requiring, and critical COVID-19 were 13/123 (10.6 %), 14/29 (48.3 %), and 23/29 (79.3 %) before 37 weeks and 3/123 (2.4 %), 4/29 (13.8 %), and 14/29 (48.3 %) before 32 weeks, respectively. One neonate (0.5 %; 95 %CI 0.01-2.9) in the critical group died from prematurity. COVID-19 can be responsible for significant rates of severe acute, potentially deadly, respiratory distress syndromes. The most vulnerable pregnant women, those with comorbidities, may benefit particularly from prevention measures such as a lockdown.
Identifiants
pubmed: 32505805
pii: S2468-7847(20)30170-7
doi: 10.1016/j.jogoh.2020.101826
pmc: PMC7270811
pii:
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
101826Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dr Sentilhes reported consultancy work for Ferring laboratories. No other disclosures were reported.
Références
Am J Obstet Gynecol. 2020 Jul;223(1):111.e1-111.e14
pubmed: 32335053
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
N Engl J Med. 2020 Jun 18;382(25):e100
pubmed: 32302077
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
JAMA. 2020 May 19;323(19):1915-1923
pubmed: 32275295
Lancet Infect Dis. 2020 May;20(5):559-564
pubmed: 32220284
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Obstet Gynecol MFM. 2020 May;2(2):100118
pubmed: 32292903
Pharmacol Res. 2020 Jul;157:104833
pubmed: 32302706
J Am Heart Assoc. 2020 Apr 7;9(7):e016509
pubmed: 32233753
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Placenta. 2006 Feb-Mar;27(2-3):200-7
pubmed: 16338465